Patents by Inventor Shi-Shan Mao

Shi-Shan Mao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV protease substrates
    Patent number: 7834145
    Abstract: The present invention features HCV NS3 protease substrates containing a europium label and a quenching group. The europium label and quenching group are located on different sides of an ester HCV NS3 protease cleavage site. The substrate can be used in a time-resolved fluorescence (TRF) assay to measure HCV protease activity.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: November 16, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shi-Shan Mao, S. Dale Lewis
  • HCV Protease substrates
    Publication number: 20090215101
    Abstract: The present invention features HCV NS3 protease substrates containing a europium label and a quenching group. The europium label and quenching group are located on different sides of an ester HCV NS3 protease cleavage site. The substrate can be used in a time-resolved fluorescence (TRF) assay to measure HCV protease activity.
    Type: Application
    Filed: March 17, 2006
    Publication date: August 27, 2009
    Inventors: Shi-Shan Mao, S. Dale Lewis
  • Process for producing activated thrombin-activatable fibrinolysis inhibitor
    Patent number: 7176008
    Abstract: The invention is a process for purifying TAFIa from a serum sample in the presence of a reversible inhibitor of TAFIa. The invention is also a method of measuring the activity of TAFIa in the presence of a reversible inhibitor.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: February 13, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Shi-Shan Mao, Dennis Colussi, Steve Gardell
  • Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
    Publication number: 20040259934
    Abstract: Infection by a Coronaviridae virus (e.g., a coronavirus) and/or illness due to a Coronaviridae virus are treated or protected against by administration of a therapeutically or prophylactically effective amount of certain nucleoside compounds and derivatives thereof, either alone or in a composition comprising the nucleoside compound or its derivative and a pharmaceutically acceptable carrier. In addition, replication of a Coronaviridae virus is inhibited by administration of the nucleoside compounds and derivatives thereof, either alone or in pharmaceutical compositions. The nucleosides are particularly suitable for use in treating or prophylaxis of an infection by the SARS virus and/or in treating or prophylaxis of SARS, and for use in inhibiting replication of the SARS virus. The nucleoside compounds and derivatives can optionally be administered in combination with other agents active against the Coronaviridae virus and/or an illness due to the virus.
    Type: Application
    Filed: April 27, 2004
    Publication date: December 23, 2004
    Inventors: David B. Olsen, Joanne E. Tomassini, Shi-Shan Mao, Steven S. Carroll
  • Process for producing activated thrombin-activatable fibrinolysis inhibitor
    Publication number: 20040126815
    Abstract: The invention is a process for purifying TAFIa from a serum sample in the presence of a reversible inhibitor of TAFIa. The invention is also a method of measuring the activity of TAFIa in the presence of a reversible inhibitor.
    Type: Application
    Filed: December 16, 2003
    Publication date: July 1, 2004
    Inventors: Shi-Shan Mao, Dennis Colussi, Steve Gardell
  • Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor
    Publication number: 20030035795
    Abstract: The invention includes methods for treating or reducing the risk of inflammation in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor. Such diseases include but are not limited to nephritis, systemic lupus erythematosus, rheumatoid arthritis, glomerulonephritis, and sacoidosis. The invention includes methods for treating or reducing the risk of pain in a patient which comprises treating the patient with an inhibitor of activated thrombin activatable fibrinolysis inhibitor.
    Type: Application
    Filed: April 11, 2002
    Publication date: February 20, 2003
    Inventors: Stephen J. Gardell, Shi-Shan Mao